Equities
Health CareHealth Care Providers
  • Price (USD)58.04
  • Today's Change-0.56 / -0.96%
  • Shares traded7.00m
  • 1 Year change-19.55%
  • Beta0.4576
Data delayed at least 15 minutes, as of Nov 14 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy3
Outperform7
Hold10
Sell0
Strong Sell0

Share price forecast in USD

The 16 analysts offering 12 month price targets for Centene Corp have a median target of 85.50, with a high estimate of 95.00 and a low estimate of 66.00. The median estimate represents a 45.90% increase from the last price of 58.60.
High62.1%95.00
Med45.9%85.50
Low12.6%66.00

Earnings history & estimates in USD

On Oct 25, 2024, Centene Corp reported 3rd quarter 2024 earnings of 1.62 per share. This result exceeded the 1.33 consensus of the 16 analysts covering the company and under-performed last year's 3rd quarter results by 19.00%.
The next earnings announcement is expected on Feb 04, 2025.
Average growth rate+74.69%
Centene Corp reported annual 2023 earnings of 6.68 per share on Feb 06, 2024.
Average growth rate+10.98%
More ▼

Revenue history & estimates in USD

Centene Corporation had 3rd quarter 2024 revenues of 42.02bn. This bettered the 37.60bn consensus of the 13 analysts covering the company. This was 8.06% above the prior year's 3rd quarter results.
Average growth rate+2.55%
Centene Corporation had revenues for the full year 2023 of 154.00bn. This was 6.54% above the prior year's results.
Average growth rate+20.88%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.